Safety, Tolerability and Pharmacokinetics of DCBCI0901 in Patients With Advanced Solid Tumor

Summary

* Investigate the safety and tolerability of multiple DCBCI0901 infusions in patients with advanced solid tumor * Pharmacokinetic parameters will be calculated for DCBCI0901, if data permit. * Anti tumor activity: The efficacy endpoint will be the overall response rate (ORR) defined as the proportion of patients who continuously receive treatment after Cycle 1 with a best overall response of complete response (CR) or partial response (PR).

Timeline

Start

2014-08-19

Primary completion

2016-06-24

Completion

2016-10-31

Outcome

Outcome not reported

Stopped: “catheter occlusion events during the study drug infusion”

Drugs

Indications